CRMDCorMedix Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−26% a year). The price bakes in little to no growth.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CRMD's price assumes
CorMedix Inc. trades at 3.82× earnings against 19.8× for the median Biotechnology name, cheaper than its own group.
Trailing P/E · Biotechnology median 19.8 · cheaper than the typical name in its group
- Price / sales
- 1.57
Price / sales · as of 2026-Q2
- Free cash flow yield
- 41%
Free cash flow yield · Biotechnology median 4.3%
- Growth the price implies
- −26%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Price / bookas of 2026-Q2
- 1.58
- Healthcare median P/E503 names
- 27.9
- Biotechnology median P/E242 names
- 19.8
- Free cash flow, trailing twelve months
- $250M
- Market capitalisation77.9 million shares, counted Aug 10, 2026
- $611M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.